The FDA has accepted Sarepta's applications for Amondys 45 and Vyondys 53, setting a target decision date of February 28, 2027, for full approval of these Duchenne muscular dystrophy (DMD) treatments. The applications are supported by clinical and real-world data showing positive trends in protein production and slowed functional decline. Following the announcement, Sarepta's shares rose, despite mixed ratings from analysts regarding the company's long-term performance.

Sarepta Therapeutics is advancing towards full FDA approval for its Duchenne Muscular Dystrophy drugs, VYONDYS 53 and AMONDYS 45. The FDA has accepted supplemental New Drug Applications, setting a target action date of February 28, 2027. This move is supported by data from the Phase 3 ESSENCE study and real-world evidence showing preserved muscle function and slower disease progression in patients treated with these exon-skipping therapies.

This page provides access to financial disclosures and regulatory filings for Tandem Diabetes Care, Inc., specifically for its unsponsored Brazilian Depositary Receipts (T2ND34). It lists various documents from 2025 and 2026, including earnings reports, conference transcripts, and corporate presentations, offering insights into the company's performance, strategy, and upcoming products. The documents cover key events such as the Goldman Sachs and Bank of America Healthcare Conferences, quarterly earnings calls, and the company's annual general meeting.

AT&T Inc. stock (T) dropped by 4.65% on June 30 due to several factors including an Oppenheimer downgrade, increasing competition from satellite broadband providers like Starlink, and skepticism surrounding AT&T's aggressive fiber-optic expansion strategy. Additionally, regulatory risks, legacy lead cable liabilities, and the upcoming retirement of CFO Pascal Desroches contributed to the stock's decline. These combined headwinds overshadowed the company's attractive dividend yield and cash flows.

Arista Networks Inc (ANET) stock rose by 3.79% on June 30th, driven by increased revenue guidance, higher chip purchase commitments, and strong institutional investor interest. Despite recent executive insider selling and a generally bearish market sentiment, analysts maintain a strong buy rating due to robust fundamentals, a zero-debt balance sheet, and a new AI-focused product portfolio. The upward move signals a recovery after recent downward pressure, reinforcing the company's strong position in the AI infrastructure market.

Eaton Corporation PLC (ETN) stock rose 3.79% due to its inclusion in several Russell Growth indices, attracting significant institutional investment. The company's strategic decision to spin off its Mobility Group will allow it to focus on higher-growth electrical and aerospace segments. Additionally, strong demand from the AI infrastructure boom and record electrical backlogs are contributing to increased analyst earnings estimates and a positive outlook for ETN.

|Ulta Beauty's in-store partnership with Target is ending this summer, to be replaced by Target's new "Beauty Studio." This new section will launch in over 600 stores and online this fall, featuring more than 80 global, prestige brands, with 60 being new to Target. The initiative aims to enhance Target's beauty offerings with a curated selection, exclusive launches, and specific Target Circle rewards.

Brodsky & Smith LLC is investigating potential breaches of fiduciary duties by the boards of directors of Nuvalent, Inc. (NUVL), Dana Incorporated (DAN), SUNation Energy, Inc. (SUNE), and Taylor Morrison Home Corporation (TMHC) in connection with their proposed acquisition/merger deals. The investigations focus on whether fair processes were conducted and whether the transactions offer fair value to the companies' shareholders. Investors are encouraged to contact Brodsky & Smith for discussions regarding these investigations.

Linde (LIN) is presented as a strong buy-and-hold investment due to its robust business model, consistent dividend growth, and resilience during economic downturns. The company's "take-or-pay" contracts, significant backlog, and high operating margins ensure long-term stability. While it may lag in fast-paced bull markets, its attributes make it an ideal choice for retirement-focused investors seeking long-duration, low-maintenance allocation.

Taco Bell, a brand known for innovation and value, is now focusing on operational excellence as a key competitive advantage. This strategic shift allows the company to consistently deliver new menu items with fast, reliable service, leading to improved customer satisfaction and eight consecutive quarters of same-store sales growth. By streamlining restaurant operations and leveraging insights from across Yum!'s global system, Taco Bell aims to support its rapid innovation pipeline while enhancing both team member and guest experiences.